J. Molner AS (Nasdaq Tallinn: MOLNR) today announced the launch of its new product in the United States: Desoximetasone Ointment USP, 0.05%. The new product launch is another step in the company’s strategy to create an international platform for its pharmaceutical products.

Desoximetasone Ointment USP, 0.05%, is a prescription-only corticosteroid medication designed to reduce inflammation and itching caused by skin conditions.

“Our launch of Desoximetasone Ointment USP, 0.05% represents another step forward for J. Molner AS,” remarked Jason Grenfell-Gardner, Founder of the company. “The product, originally developed by a third party, was acquired by J. Molner. Our team successfully managed all Post-Approval Change requirements to reintroduce the product to the market in compliance with US regulatory standards.”

J. Molner AS remains dedicated to steady growth and advancing pharmaceutical development to bring high-quality solutions to the market.

For additional information about J. Molner AS, please visit www.jmolner.com.